195 related articles for article (PubMed ID: 24255164)
1. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
2. Anti-signal recognition particle autoantibody ELISA validation and clinical associations.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2015 Jul; 54(7):1194-9. PubMed ID: 25524922
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
4. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
[TBL] [Abstract][Full Text] [Related]
5. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies.
Cavazzana I; Richards M; Bentow C; Seaman A; Fredi M; Giudizi MG; Palterer B; Pratesi F; Migliorini P; Franceschini F; Satoh M; Ceribelli A; Mahler M
J Immunol Methods; 2019 Nov; 474():112661. PubMed ID: 31442464
[TBL] [Abstract][Full Text] [Related]
7. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
9. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
11. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
12. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
14. The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population.
Loganathan A; McMorrow F; Lu H; Li D; Mulhearn B; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():975939. PubMed ID: 36177007
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA; Pak K; Pinal-Fernandez I; Flegel WA; Targoff IN; Miller FW; Rider LG; Mammen AL;
Arthritis Rheumatol; 2023 Sep; 75(9):1668-1677. PubMed ID: 36996276
[TBL] [Abstract][Full Text] [Related]
16. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
17. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
18. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
19. Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera.
Muro Y; Yamano Y; Yoshida K; Oto Y; Nakajima K; Mitsuma T; Kikuchi S; Matsumae A; Ogawa-Momohara M; Takeichi T; Kondoh Y; Katayama M; Todoroki Y; Tanaka Y; Satoh M; Akiyama M
J Autoimmun; 2021 Aug; 122():102680. PubMed ID: 34120070
[TBL] [Abstract][Full Text] [Related]
20. Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay.
Mahler M; Swart A; Wu J; Szmyrka-Kaczmarek M; Senécal JL; Troyanov Y; Hanly JG; Fritzler MJ
Lupus; 2016 Jul; 25(8):889-96. PubMed ID: 27252266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
